Trump Unveils Deal To Lower Costs On Obesity Drugs

WASHINGTON (AP) — President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy. The drugs are part of a new generation of obesity medications known as GLP-1 receptor agonists that have soared in popularity in recent years. But access to the drugs has been a consistent problem for patients because of their cost and spotty insurance coverage. Thursday’s announcement is the latest attempt by the Trump administration to rein in soaring drug prices in its efforts to address cost-of-living concerns among voters.